⟵ Back to Search Results
BGB-A317-A1217-301

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Beigene Study ID info

BGB-A317-A1217-301

ClinicalTrials.gov ID info

NCT04866017

EudraCT Number info

2020-004656-14

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents